MedTrace Logo

Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity

NCT01724450 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate if carvedilol can prevent the cardiotoxicity after chemotherapy in breast cancer.

Conditions

Interventions

DRUG

Carvedilol

50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day

DRUG

Placebo

Placebo similar to the carvedilol up titration but wit no active drug.

Sponsors & Collaborators

  • Hospital A.C. Camargo

    collaborator OTHER

  • Instituto do Cancer do Estado de São Paulo

    collaborator OTHER

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Edimar Alcides Bocchi, PHD · Heart Institute of University of Sao Paulo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724450 on ClinicalTrials.gov